284 related articles for article (PubMed ID: 17907171)
1. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis.
Jochems C; Islander U; Kallkopf A; Lagerquist M; Ohlsson C; Carlsten H
Arthritis Rheum; 2007 Oct; 56(10):3261-70. PubMed ID: 17907171
[TBL] [Abstract][Full Text] [Related]
2. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation.
Jochems C; Islander U; Erlandsson M; Verdrengh M; Ohlsson C; Carlsten H
Arthritis Res Ther; 2005; 7(4):R837-43. PubMed ID: 15987485
[TBL] [Abstract][Full Text] [Related]
4. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
5. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
6. Modulation of survival in osteoblasts from postmenopausal women.
García-Moreno C; Catalán MP; Ortiz A; Alvarez L; De la Piedra C
Bone; 2004 Jul; 35(1):170-7. PubMed ID: 15207753
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
8. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
10. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis.
Jochems C; Lagerquist M; Håkansson C; Ohlsson C; Carlsten H
Clin Exp Immunol; 2008 Jun; 152(3):593-7. PubMed ID: 18435803
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice.
Erlandsson MC; Gömöri E; Taube M; Carlsten H
Cell Immunol; 2000 Nov; 205(2):103-9. PubMed ID: 11104582
[TBL] [Abstract][Full Text] [Related]
12. Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis.
Jochems C; Islander U; Erlandsson M; Engdahl C; Lagerquist M; Gjertsson I; Ohlsson C; Holmdahl R; Carlsten H
BMC Musculoskelet Disord; 2010 Dec; 11():284. PubMed ID: 21159208
[TBL] [Abstract][Full Text] [Related]
13. Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast.
Irie T; Takahata M; Majima T; Abe Y; Komatsu M; Iwasaki N; Minami A
Connect Tissue Res; 2010 Jun; 51(3):179-87. PubMed ID: 20073985
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
15. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.
Engdahl C; Jochems C; Gustafsson JA; van der Saag PT; Carlsten H; Lagerquist MK
J Endocrinol; 2009 Dec; 203(3):349-56. PubMed ID: 19752149
[TBL] [Abstract][Full Text] [Related]
16. Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis.
Jochems C; Islander U; Erlandsson M; Engdahl C; Lagerquist M; Ohlsson C; Nandakumar KS; Holmdahl R; Carlsten H
Clin Exp Immunol; 2011 Jul; 165(1):121-9. PubMed ID: 21501150
[TBL] [Abstract][Full Text] [Related]
17. Morphologic effects of epithelial ion channels on the mouse uterus: differences between raloxifene analog (LY117018) and estradiol treatments.
Nobuzane T; Tashiro S; Kudo Y
Am J Obstet Gynecol; 2008 Oct; 199(4):363.e1-6. PubMed ID: 18456231
[TBL] [Abstract][Full Text] [Related]
18. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
Pullerits R; d'Elia HF; Tarkowski A; Carlsten H
Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.
Heilberg IP; Hernandez E; Alonzo E; Valera R; Ferreira LG; Gomes SA; Bellorin-Font E; Weisinger JR
Ren Fail; 2005; 27(2):155-61. PubMed ID: 15807179
[TBL] [Abstract][Full Text] [Related]
20. Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis.
Stubelius A; Andréasson E; Karlsson A; Ohlsson C; Tivesten A; Islander U; Carlsten H
Clin Immunol; 2011 Jul; 140(1):37-46. PubMed ID: 21459677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
